Pharmacokinetics, safety, and hydrolysis of oral pyrroloquinazolinediamines administered in single and multiple doses in rats

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 2898-2904

  Li, Qigui ^a   Kozar, Michael P ^a   Shearer, Todd W ^a   Xie, Lisa H ^a   Lin, Ai J ^a   Smith, Kirsten S ^a   Si, Yuanzheng ^a   Anova, Lalaine ^a   Zhang, Jing ^a   Milhous, Wilbur K ^a   Skillman, Donald R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISETHYLCARBAMYL PYRROLOQUINAZOLINEDIAMINE; DRUG METABOLITE; PYRROLE DERIVATIVE; PYRROLOQUINAZOLINEDIAMINE; QUINAZOLINE DERIVATIVE; TETRAACETAMIDE PYRROLOQUINAZOLINEDIAMINE; UNCLASSIFIED DRUG; WR 227825;

ADOLESCENT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANOREXIA; ANTIMALARIALS; BIOLOGICAL AVAILABILITY; HYDROLYSIS; MALE; MAXIMUM TOLERATED DOSE; PYRROLES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34547637271     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00932-06     Document Type: Article

References (27)

1. Blum, J. L. 2001. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56-64.
2. Burghaus, P. A., B. T. Wellde, T. Hall, R. L. Richards, A. F. Egan, E. M. Riley, W. R. Ballou, and A. A. Holder. 1996. Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infect. Immun. 64:3614-3619.
3. Carlton, J., and N. Rowland. 1985. Effects of initial body weight on anorexia and tolerance to fenfluramine in rats. Pharmacol. Biochem. Behav. 23:551-554.
4. Chaney, S. G., G. R. Gibbons, S. D. Wyrick, and P. Podhasky. 1991. An unexpected biotransformation pathway for tetrachloro-(d, 1-trans)-1, 2-diaminocyclohexaneplatinum (IV) (tetraplatin) in the L1210 cell line. Cancer Res. 51:969-973.
5. Cody, R. P., and J. K. Smith. 1987. Applied statistics and the SAS programming language. North Holland Press, New York, NY.
6. Coners, H., H. Remschmidt, and J. Hebebrand. 1999. The relationship between premorbid body weight, weight loss, and weight at referral in adolescent patients with anorexia nervosa. Int. J. Eating Disord. 26:171-178.
7. Davoll, J., A. M. Johnson, H. J. Davies, O. D. Bird, J. Clarke, and E. F. Elslager. 1972. Folate antagonists. 2. 2,4-Diamino-6-((aralkyl and (heterocyclic)methyl)amino)quinazolines, a novel class of antimetabolites of interest in drug-resistant malaria and Chagas' disease. J. Med. Chem. 15:812-826.
8. Dominguez, J. N., J. E. Charris, G. Lobo, N. G. de Dominguez, M. M. Moreno, F. Rigginoe, E. Sanchez, J. Olson, and P. J. Rosenthal. 2001. Synthesis of quinolinyl vhalcones and evaluation of their antimalrial activity. Eur. J. Med. Chem. 36:555-560.
9. Egron, D., J.-L. Imbach, G. Gosselin, A.-M. Aubertin, and C. Perrigaud. 2003. S-acyl-2-thioethyl phosphoramidate diester derivatives as mononucleotide derivativess. J. Med. Chem. 46:4564-4571.
10. Elslager, E. F., O. D. Bird, J. Clarke, S. C. Perricone, and D. F. Worth. 1972. Folate antagonists. 9. 2,4-Diamino-6-((aralkyl)alkylamino) quinazolines, a potent class of antimetabolites with prodigious antimalarial effects. J. Med. Chem. 15:1138-1146.
11. Guan, J., Q. Zhang, M. O'Neil, N. Obaldia III, A. Ager, L. Gerena, and A. J. Lin. 2005. Antimalarial activities of new pyyolo[3,2-f]quinazoline-1, 3-diamine derivatives. Antimicrob. Agents Chemother. 49:4928-4933.
12. Hitchings, G. H. 1978. The metabolism of Plasmodia and the chemotherapy of malarial infections, p. 79-98. In C. Wood (ed.), Tropical medicine from romance to reality. Academic Press, London, United Kingdom.
13. Jones, T. R., D. F. Stroncek, A. S. Gozalo, N. Obaldia III, E. M. Andersen, C. Lucas, D. L. Narum, A. J. Magill, B. K. Sim, and S. L. Hoffman. 2002. Anemia in parasite- and recombinant protein-immunized aotus monkeys infected with Plasmodium falciparum. Am. J. Trop. Med. Hyg. 66:672-679.
14. Jorgensen, R. J. 1980. Dictyocaulus viviparous: migration in agar of larvae subjected to a variety of physicochemical exposure. Exp. Parasitol. 49:106-115.
15. Ledig, K. W. October 1978. 7-(Substituted)-7H-pyrrolo[3,2,-f] quinazoline-1,3-diamines. U.S. patent US4118561.
16. Lennie, T. A. 1998. Relationship of body energy status to inflammation-induced anorexia and weight loss. Physiol. Behav. 64:475-481.
17. Li, Q. G., S. R. Mog, Y. Z. Si, D. E. Kyle, M. Gettayacamin, and W. K. Milhous. 2002. Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. Am. J. Trop. Med. Hug. 66:516-525.
18. Li, Q. G., L. H. Xie, Y. Z. Si, E. Wong, R. Upadhyay, D. Yanez, and P. J. Weina. 2005. Toxicokinetics and hydrolysis of artelinate and artesunate in malaria-infected rats. Int. J. Toxicol. 24:241-250.
19. Mayer, P. R. 1995. Absorption, metabolism, and other factors that influence drug exposure in toxicology studies. Toxicol. Pathol. 23:165-169.
20. Rangan, U., C. Hedli, M. Gallo, P. Lioy, and R. Snyder. 1997. Exposure and risk assessment with respect to contaminated soil: significance of biomarkers and bioavailability. Int. J. Toxicol. 16:419-432.
21. Rioja, I., M. C. Terencio, A. Ubeda, P. Molina, A. Tarraga, P. Gonzalez-Tejero, and M. J. Alcaraz. 2002. A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase. Eur. J. Pharmacol. 434:177-185.
22. Rozman, K. K. 1998. Quantitative definition of toxicity: a mathematical description of life and death with dose and time as variables. Med. Hypotheses 51:175-178.
23. Rozman, K. K., and J. Doull. 2000. Dose and time as variable of toxicity. Toxicology 144:169-178.
24. Scheller, L. F., K. C. Stump, and A. F. Azad. 1995. Plasmodium berghei: production and quantitation of hepatic stages derived from irradiated sporozoites in rats and mice. J. Parasitol. 81:58-62.
25. Shargel, L., and A. B. C. Yu. 1993. Multiple-dosage regimens, p. 353-374. In L. Shargel and A. B. C. Yu (ed.), Applied biopharmaceutics and pharmacokinetics. Appleton & Lange, Norwalk, CT.
26. Venturini, M. 2002. Rational development of capecitabine. Eur. J. Cancer 38:S3-S9.
27. Xie, L. H., Q. G. Li, A. J. Lin, K. Smith, J. Zhang, and D. S. Skillman. 2006. New potential antimalarial agents: therapeutic-index evaluation of pyrroloquinazolinediamine and its prodrugs in a rat model of severe malaria. Antimicrob. Agents Chemother. 50:1649-1655.